Pub Date : 2026-02-01DOI: 10.1016/j.eimce.2025.503040
Jordi Martinez-Matencio, Inmaculada Palacios-Garcia, Eduardo Cantón-Puig, José Garnacho-Montero
{"title":"A rare case of purulent pericarditis secondary to Streptococcus constellatus due to contiguity of a liver lesion under study","authors":"Jordi Martinez-Matencio, Inmaculada Palacios-Garcia, Eduardo Cantón-Puig, José Garnacho-Montero","doi":"10.1016/j.eimce.2025.503040","DOIUrl":"10.1016/j.eimce.2025.503040","url":null,"abstract":"","PeriodicalId":72916,"journal":{"name":"Enfermedades infecciosas y microbiologia clinica (English ed.)","volume":"44 2","pages":"Article 503040"},"PeriodicalIF":0.0,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145897080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01DOI: 10.1016/j.eimce.2026.503056
Concha Amador , Juan Ambrosioni , Luz Martín-Carbonero , Carmen Hidalgo-Tenorio , Juan Tiraboschi , Santiago Moreno
Integrase strand inhibitor (INSTI)-based antiretroviral regimens are the preferred choices for treating people with human immunodeficiency virus (PWH). The once-daily single-tablet combination of INSTI bictegravir, co-formulated with emtricitabine and tenofovir alafenamide (BIC/FTC/TAF), has shown effectiveness and good tolerability in randomized clinical trials, both in treatment-naïve (TN) and virologically suppressed patients switched to this regimen. Real-world evidence represents clinical practice and may fill data gaps left by pivotal studies. Based on literature search for real-world studies in Spain within five years, and using clinical trial data as a contextual framework, this narrative review synthesizes observational experience with BIC/FTC/TAF, focusing on the interplay between comorbidities, advanced age, and treatment outcomes from underrepresented subgroups in clinical trials. This fixed-dose combination proved effective and well-tolerated for TN and treatment-experienced PWH, with low virological failure even in difficult-to-treat patients. Low rates of treatment discontinuations due to adverse events or drug-drug interactions aligned with clinical trial findings.
{"title":"Bictegravir/emtricitabine/tenofovir alafenamide: A review of the real-world experience in Spain within the last five years","authors":"Concha Amador , Juan Ambrosioni , Luz Martín-Carbonero , Carmen Hidalgo-Tenorio , Juan Tiraboschi , Santiago Moreno","doi":"10.1016/j.eimce.2026.503056","DOIUrl":"10.1016/j.eimce.2026.503056","url":null,"abstract":"<div><div>Integrase strand inhibitor (INSTI)-based antiretroviral regimens are the preferred choices for treating people with human immunodeficiency virus (PWH). The once-daily single-tablet combination of INSTI bictegravir, co-formulated with emtricitabine and tenofovir alafenamide (BIC/FTC/TAF), has shown effectiveness and good tolerability in randomized clinical trials, both in treatment-naïve (TN) and virologically suppressed patients switched to this regimen. Real-world evidence represents clinical practice and may fill data gaps left by pivotal studies. Based on literature search for real-world studies in Spain within five years, and using clinical trial data as a contextual framework, this narrative review synthesizes observational experience with BIC/FTC/TAF, focusing on the interplay between comorbidities, advanced age, and treatment outcomes from underrepresented subgroups in clinical trials. This fixed-dose combination proved effective and well-tolerated for TN and treatment-experienced PWH, with low virological failure even in difficult-to-treat patients. Low rates of treatment discontinuations due to adverse events or drug-drug interactions aligned with clinical trial findings.</div></div>","PeriodicalId":72916,"journal":{"name":"Enfermedades infecciosas y microbiologia clinica (English ed.)","volume":"44 2","pages":"Article 503056"},"PeriodicalIF":0.0,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146116799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01DOI: 10.1016/j.eimce.2026.503059
Maria Giulia Caponcello , María Del Rocío Fernández-Ojeda , Natalia Maldonado , Manuel Diéguez-Serrano , Ana Laura Blanco-Taboada , Paula Olivares Navarro , Adriana Rivera-Sequeiros , Rafael Perera , Jose A. Delgado-Torralbo , Luisa González-Iglesias , Miguel A. Rico-Corral , María Dolores Del Toro , Jesús Rodríguez-Baño , Zaira R. Palacios-Baena , Belén Gutiérrez-Gutiérrez
Introduction
The FEN-COVID study identified 3 clinical phenotypes (PhA, PhB and PhC) in hospital-admitted patients with COVID-19, which were associated with mortality. The aim of this study is to validate the assignment to phenotypes and their association with mortality in two hospitals in Spain across the first 4 waves of the pandemic, including the impact of corticosteroids and anticoagulant drugs.
Methods
A prospective cohort study of patients admitted for COVID-19 in the first 4 waves in two hospitals was performed. Phenotypes were assigned using the FEN-COVID calculator. The primary outcome was 30-day all-cause mortality. Kaplan–Meier (KM) curves were compared using the log-rank test. Multivariate analysis was performed using Cox regression analysis to assess the association of phenotypes with mortality.
Results
1839 patients were included. Of these, 257 patients were identified as PhA, 1451 as PhB and 130 as PhC; their 30-day mortality was 1.9%, 15.4% and 45.4%, respectively. In multivariate analysis and controlling for wave effect, belonging to phenotype B and phenotype C was associated with progressive increased hazards of death. In addition, appropriate treatment with corticosteroids was significantly associated with lower mortality in PhB, while low-molecular weight heparin use was significantly associated with lower mortality in PhB and PhC.
Conclusions
Our results confirmed that the clinical phenotypes identified in the FEN-COVID study were predictive of mortality across all waves studied. Furthermore, we confirmed the importance of identifying the phenotype to which a patient belongs on admission when considering appropriate treatment with corticosteroids and/or anticoagulants.
{"title":"Validation of FEN-COVID phenotypes in hospitalised COVID-19 patients across the first four waves of the pandemic","authors":"Maria Giulia Caponcello , María Del Rocío Fernández-Ojeda , Natalia Maldonado , Manuel Diéguez-Serrano , Ana Laura Blanco-Taboada , Paula Olivares Navarro , Adriana Rivera-Sequeiros , Rafael Perera , Jose A. Delgado-Torralbo , Luisa González-Iglesias , Miguel A. Rico-Corral , María Dolores Del Toro , Jesús Rodríguez-Baño , Zaira R. Palacios-Baena , Belén Gutiérrez-Gutiérrez","doi":"10.1016/j.eimce.2026.503059","DOIUrl":"10.1016/j.eimce.2026.503059","url":null,"abstract":"<div><h3>Introduction</h3><div>The FEN-COVID study identified 3 clinical phenotypes (PhA, PhB and PhC) in hospital-admitted patients with COVID-19, which were associated with mortality. The aim of this study is to validate the assignment to phenotypes and their association with mortality in two hospitals in Spain across the first 4 waves of the pandemic, including the impact of corticosteroids and anticoagulant drugs.</div></div><div><h3>Methods</h3><div>A prospective cohort study of patients admitted for COVID-19 in the first 4 waves in two hospitals was performed. Phenotypes were assigned using the FEN-COVID calculator. The primary outcome was 30-day all-cause mortality. Kaplan–Meier (KM) curves were compared using the log-rank test. Multivariate analysis was performed using Cox regression analysis to assess the association of phenotypes with mortality.</div></div><div><h3>Results</h3><div>1839 patients were included. Of these, 257 patients were identified as PhA, 1451 as PhB and 130 as PhC; their 30-day mortality was 1.9%, 15.4% and 45.4%, respectively. In multivariate analysis and controlling for wave effect, belonging to phenotype B and phenotype C was associated with progressive increased hazards of death. In addition, appropriate treatment with corticosteroids was significantly associated with lower mortality in PhB, while low-molecular weight heparin use was significantly associated with lower mortality in PhB and PhC.</div></div><div><h3>Conclusions</h3><div>Our results confirmed that the clinical phenotypes identified in the FEN-COVID study were predictive of mortality across all waves studied. Furthermore, we confirmed the importance of identifying the phenotype to which a patient belongs on admission when considering appropriate treatment with corticosteroids and/or anticoagulants.</div></div>","PeriodicalId":72916,"journal":{"name":"Enfermedades infecciosas y microbiologia clinica (English ed.)","volume":"44 2","pages":"Article 503059"},"PeriodicalIF":0.0,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146116326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01DOI: 10.1016/j.eimce.2026.503074
Anju Dinkar , Jitendra Singh
Introduction
Dengue virus (DENV) infection can present a range of clinical manifestations, from mild fever to severe complications. Emerging data suggest that specific viral serotypes may influence disease severity. This study aimed to evaluate the circulating DENV serotypes and their correlation with clinical outcomes in hospitalized patients.
Methods
A retrospective, cross-sectional study was conducted at a tertiary care center in northern India from August 2022 to January 2023. Laboratory-confirmed dengue cases (N = 356) were included, and serotyping was performed via nested reverse transcription-polymerase chain reaction (nested RT-PCR). Demographic, clinical, and biochemical data were analyzed. Statistical comparisons and relative risk analyses were performed to identify associations between serotypes and disease severity, including mortality predictors.
Results
Out of the 111 dengue cases, 7 had mixed serotypes. Among the remaining 104 patients, DENV-2 was the predominant serotype (71.2%), followed by DENV-3 (26.9%), DENV-1 (1.9%), and mixed serotypes (6.3%) infections. Overall, 71.2% of patients presented with warning signs, and 28.8% progressed to severe dengue. The highest severe dengue cases were observed in DENV-2 (33.8%) and in mixed DENV-2 & 3 infections (100%). DENV-2 was significantly associated with severe manifestations such as plasma leakage (RR = 24.73, p < 0.001), hemorrhagic rash, and elevated transaminases. Mortality (21.6%) occurred exclusively in DENV-2 and mixed DENV-2 and 3 infections. Predictors of mortality included thrombocytopenia, leucopenia, elevated SGPT/SGOT, and hypoalbuminemia.
Conclusion
DENV-2 is the principal serotype associated with severe dengue and adverse outcomes in this region. Early identification of serotype and key laboratory parameters can improve risk stratification and clinical management, with implications for surveillance and public health response.
{"title":"Dengue serotypes and their severity correlation: A hospital-based observational study","authors":"Anju Dinkar , Jitendra Singh","doi":"10.1016/j.eimce.2026.503074","DOIUrl":"10.1016/j.eimce.2026.503074","url":null,"abstract":"<div><h3>Introduction</h3><div>Dengue virus (DENV) infection can present a range of clinical manifestations, from mild fever to severe complications. Emerging data suggest that specific viral serotypes may influence disease severity. This study aimed to evaluate the circulating DENV serotypes and their correlation with clinical outcomes in hospitalized patients.</div></div><div><h3>Methods</h3><div>A retrospective, cross-sectional study was conducted at a tertiary care center in northern India from August 2022 to January 2023. Laboratory-confirmed dengue cases (<em>N</em> <!-->=<!--> <!-->356) were included, and serotyping was performed via nested reverse transcription-polymerase chain reaction (nested RT-PCR). Demographic, clinical, and biochemical data were analyzed. Statistical comparisons and relative risk analyses were performed to identify associations between serotypes and disease severity, including mortality predictors.</div></div><div><h3>Results</h3><div>Out of the 111 dengue cases, 7 had mixed serotypes. Among the remaining 104 patients, DENV-2 was the predominant serotype (71.2%), followed by DENV-3 (26.9%), DENV-1 (1.9%), and mixed serotypes (6.3%) infections. Overall, 71.2% of patients presented with warning signs, and 28.8% progressed to severe dengue. The highest severe dengue cases were observed in DENV-2 (33.8%) and in mixed DENV-2 & 3 infections (100%). DENV-2 was significantly associated with severe manifestations such as plasma leakage (RR<!--> <!-->=<!--> <!-->24.73, <em>p</em> <!--><<!--> <!-->0.001), hemorrhagic rash, and elevated transaminases. Mortality (21.6%) occurred exclusively in DENV-2 and mixed DENV-2 and 3 infections. Predictors of mortality included thrombocytopenia, leucopenia, elevated SGPT/SGOT, and hypoalbuminemia.</div></div><div><h3>Conclusion</h3><div>DENV-2 is the principal serotype associated with severe dengue and adverse outcomes in this region. Early identification of serotype and key laboratory parameters can improve risk stratification and clinical management, with implications for surveillance and public health response.</div></div>","PeriodicalId":72916,"journal":{"name":"Enfermedades infecciosas y microbiologia clinica (English ed.)","volume":"44 2","pages":"Article 503074"},"PeriodicalIF":0.0,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146116322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01DOI: 10.1016/j.eimce.2026.503071
Ana Hernandez-Aceituno , Diana Sanabria Curbelo , Isabel Falcón García , Álvaro Torres Lana , Roque Abián Montesdeoca Melián , Eneko Larumbe-Zabala
Introduction
Measles, a highly contagious airborne disease, has seen a resurgence in Spain despite the successful implementation of vaccination programs. This study examines two cases of vaccine-associated measles in children attending the same nursery school, both of whom received the measles–mumps–rubella vaccine.
Methods
Retrospective descriptive study of two children with vaccine-associated measles in May 2025 on the island of Gran Canaria (Spain).
Results
The first case involved a 12-month-old girl who developed symptoms six days post-vaccination, while the second case, a 13-month-old boy, exhibited symptoms eight days after receiving the vaccine. Both cases were confirmed as genotype A, indicating the vaccine strain. The investigation included extensive contact tracing, identifying 107 close contacts, with vaccinations administered to susceptible individuals. Laboratory tests confirmed measles through polymerase chain reaction (PCR) analysis. The findings highlight the rarity of clinically significant vaccine-associated disease and the absence of evidence for human-to-human transmission of the vaccine strain.
Conclusion
This study underscores the importance of genotyping in distinguishing between vaccine-associated rash illness and wild-type measles, as well as the need for continued vigilance in monitoring vaccine efficacy and outbreak responses. Ultimately, while the possibility of transmission cannot be entirely dismissed, the evidence suggests that these cases are more likely coincidental rather than a result of transmission.
{"title":"Two vaccine-associated measles cases: Transmission or coincidental cases?","authors":"Ana Hernandez-Aceituno , Diana Sanabria Curbelo , Isabel Falcón García , Álvaro Torres Lana , Roque Abián Montesdeoca Melián , Eneko Larumbe-Zabala","doi":"10.1016/j.eimce.2026.503071","DOIUrl":"10.1016/j.eimce.2026.503071","url":null,"abstract":"<div><h3>Introduction</h3><div>Measles, a highly contagious airborne disease, has seen a resurgence in Spain despite the successful implementation of vaccination programs. This study examines two cases of vaccine-associated measles in children attending the same nursery school, both of whom received the measles–mumps–rubella vaccine.</div></div><div><h3>Methods</h3><div>Retrospective descriptive study of two children with vaccine-associated measles in May 2025 on the island of Gran Canaria (Spain).</div></div><div><h3>Results</h3><div>The first case involved a 12-month-old girl who developed symptoms six days post-vaccination, while the second case, a 13-month-old boy, exhibited symptoms eight days after receiving the vaccine. Both cases were confirmed as genotype A, indicating the vaccine strain. The investigation included extensive contact tracing, identifying 107 close contacts, with vaccinations administered to susceptible individuals. Laboratory tests confirmed measles through polymerase chain reaction (PCR) analysis. The findings highlight the rarity of clinically significant vaccine-associated disease and the absence of evidence for human-to-human transmission of the vaccine strain.</div></div><div><h3>Conclusion</h3><div>This study underscores the importance of genotyping in distinguishing between vaccine-associated rash illness and wild-type measles, as well as the need for continued vigilance in monitoring vaccine efficacy and outbreak responses. Ultimately, while the possibility of transmission cannot be entirely dismissed, the evidence suggests that these cases are more likely coincidental rather than a result of transmission.</div></div>","PeriodicalId":72916,"journal":{"name":"Enfermedades infecciosas y microbiologia clinica (English ed.)","volume":"44 2","pages":"Article 503071"},"PeriodicalIF":0.0,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146116323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-02DOI: 10.1016/j.eimce.2025.503055
Jaime R Torres, Wilmer Villamil Gómez, Octavio Arce García, Francisco Javier Membrillo de Novales
Mayaro virus (MAYV) and Oropouche virus (OROV) cause emerging infections in Latin America. They represent an increasing public health threat in this and other regions due to their geographic spread, rising case numbers, and the identification of complications and fatal cases. This review, developed by specialists from Latin America and Spain, addresses the epidemiology, pathophysiology, clinical manifestations, diagnosis, and treatment of both infections, aiming to provide valuable information for the diagnosis and management of these diseases based on updated scientific evidence. The diagnostic challenges are emphasized, particularly the clinical overlap with other arboviral infections, the lack of commercial diagnostic tools, and the urgent need for active epidemiological surveillance. The risk of undetected outbreaks is highlighted, along with the importance of including these viruses in clinical algorithms-especially in residents or travellers to endemic areas and, specifically for OROV, in pregnant women with suspected arboviral infection.
{"title":"Epidemiology, diagnosis and treatment of Mayaro and Oropouche virus infections: implication for clinical practice and public health.","authors":"Jaime R Torres, Wilmer Villamil Gómez, Octavio Arce García, Francisco Javier Membrillo de Novales","doi":"10.1016/j.eimce.2025.503055","DOIUrl":"https://doi.org/10.1016/j.eimce.2025.503055","url":null,"abstract":"<p><p>Mayaro virus (MAYV) and Oropouche virus (OROV) cause emerging infections in Latin America. They represent an increasing public health threat in this and other regions due to their geographic spread, rising case numbers, and the identification of complications and fatal cases. This review, developed by specialists from Latin America and Spain, addresses the epidemiology, pathophysiology, clinical manifestations, diagnosis, and treatment of both infections, aiming to provide valuable information for the diagnosis and management of these diseases based on updated scientific evidence. The diagnostic challenges are emphasized, particularly the clinical overlap with other arboviral infections, the lack of commercial diagnostic tools, and the urgent need for active epidemiological surveillance. The risk of undetected outbreaks is highlighted, along with the importance of including these viruses in clinical algorithms-especially in residents or travellers to endemic areas and, specifically for OROV, in pregnant women with suspected arboviral infection.</p>","PeriodicalId":72916,"journal":{"name":"Enfermedades infecciosas y microbiologia clinica (English ed.)","volume":" ","pages":"503055"},"PeriodicalIF":0.0,"publicationDate":"2026-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145897075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01DOI: 10.1016/j.eimce.2025.503038
María Aznar , Mariana G. López , María José Torres , Eduardo Briones , Juan Francisco Medina , Verónica González-Galán
Introduction
Tuberculosis (TB) in the Virgen del Rocío university hospital health area, included in the Seville Health District, Spain, exceeds the rate of 17 cases/100,000 inhabitants. Within the Mycobacterium tuberculosis complex (MTBC), M. tuberculosis sensu stricto comprises seven phylogenetic lineages (L1–L4 and L7–L9). The objective of this work is to know the circulating lineages in the area.
Methods
Molecular typing and sequencing were performed to identify circulating lineages from 2015 to 2022.
Results
From 2015 to 2019, the following were identified: L4 (95.95%, n = 355), L2 (1.62%, n = 6), and L6 (1.08%, n = 4). From 2020 to 2022: L4 94.62% (n = 123); L1 1.5% (n = 2); L3 1.5% (n = 2) and L2 0.76% (n = 1).
Conclusions
The emergence of different lineages in our area and their recognition are key to contributing to disease control. These findings demonstrate the need to continue surveillance and apply sequencing to understand and control the dynamics of TB transmission.
{"title":"Identification of lineages and sublineages of the Mycobacterium tuberculosis complex using advanced molecular strategies and WGS in Seville, Spain (2015–2022)","authors":"María Aznar , Mariana G. López , María José Torres , Eduardo Briones , Juan Francisco Medina , Verónica González-Galán","doi":"10.1016/j.eimce.2025.503038","DOIUrl":"10.1016/j.eimce.2025.503038","url":null,"abstract":"<div><h3>Introduction</h3><div>Tuberculosis (TB) in the Virgen del Rocío university hospital health area, included in the Seville Health District, Spain, exceeds the rate of 17 cases/100,000 inhabitants. Within the <em>Mycobacterium tuberculosis</em> complex (MTBC), <em>M. tuberculosis sensu stricto</em> comprises seven phylogenetic lineages (L1–L4 and L7–L9). The objective of this work is to know the circulating lineages in the area.</div></div><div><h3>Methods</h3><div>Molecular typing and sequencing were performed to identify circulating lineages from 2015 to 2022.</div></div><div><h3>Results</h3><div>From 2015 to 2019, the following were identified: L4 (95.95%, n = 355), L2 (1.62%, n = 6), and L6 (1.08%, n = 4). From 2020 to 2022: L4 94.62% (n = 123); L1 1.5% (n = 2); L3 1.5% (n = 2) and L2 0.76% (n = 1).</div></div><div><h3>Conclusions</h3><div>The emergence of different lineages in our area and their recognition are key to contributing to disease control. These findings demonstrate the need to continue surveillance and apply sequencing to understand and control the dynamics of TB transmission.</div></div>","PeriodicalId":72916,"journal":{"name":"Enfermedades infecciosas y microbiologia clinica (English ed.)","volume":"44 1","pages":"Article 503038"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145897096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01DOI: 10.1016/j.eimce.2025.503044
Iñaki Comas
{"title":"Increasing clinical and public health role of Mycobacterium tuberculosis genomics","authors":"Iñaki Comas","doi":"10.1016/j.eimce.2025.503044","DOIUrl":"10.1016/j.eimce.2025.503044","url":null,"abstract":"","PeriodicalId":72916,"journal":{"name":"Enfermedades infecciosas y microbiologia clinica (English ed.)","volume":"44 1","pages":"Article 503044"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145957848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号